Table 3.

Associations between baseline fentanyl use and persistence on 1) any medications for opioid use disorder (MOUD) and 2) assigned study MOUD (N = 76 participants initiating MOUD with duration data).

	Mean (sd), Median	IRRa (95% CI); p	Adjusted IRRb (95% CI); p
Any MOUD
Fentanyl positive	3.07 (1.73), 3	0.94 (0.70, 1.27); .689	0.99 (0.69, 1.42); .953
Fentanyl negative	3.19 (1.99), 3	Ref	Ref
Assigned study medication
XR-NTX
Fentanyl positive	2.78 (1.86), 2	0.82 (0.49, 1.35); .426	0.97 (0.48, 1.95); .927
Fentanyl negative	3.64 (2.21), 4	Ref	Ref
TAUc
Fentanyl positive	3.13 (1.75), 3	1.23 (0.79, 1.94); .362	1.27 (0.78, 2.07); .338
Fentanyl negative	2.50 (1.56), 2.5	Ref	Ref
Buprenorphine
Fentanyl positive	2.71 (1.45), 3	1.09 (0.69, 1.75); .702	1.17 (0.71, 1.94); .537
Fentanyl negative	2.50 (1.56), 2.5	Ref	Ref

^aAdjusted for study site only

^bAdjusted for study site, age, sex, race, ethnicity, severity of substance use, anxiety or depression, and stimulant, benzodiazepine, and other opioid use

^cTreatment as usual includes buprenorphine or methadone